ImaginAb Inc., a global biotechnology company developing advanced imaging radiopharmaceuticals, today announced a new collaboration to support an investigator-initiated trial at Memorial Sloan Kettering Cancer Center (MSK).
The study, led by principal investigator Dr. Adam Schoenfeld, is titled, “Assessment of Patients’ Immune Response After Treatment with Engineered Tumor Infiltrating Lymphocyte Therapy Incorporating CD8 PET Imaging.”
This groundbreaking trial aims to leverage ImaginAb’s proprietary lead investigational imaging agent, 89Zr crefmirlimab berdoxam (CD8 ImmunoPET) to assess immune responses in vivo in patients undergoing engineered tumor-infiltrating lymphocyte (TIL) therapy.
Dr. Adam Schoenfeld, a renowned expert in immuno-oncology, will oversee the trial at MSK, one of the world’s leading cancer treatment and research institutions. The study highlights the growing role of CD8 ImmunoPET imaging as a valuable tool in advancing immunotherapy research and clinical care.
ImaginAb is excited to support this intriguing investigator-initiated trial at Memorial Sloan Kettering Cancer Center. “We are thankful for the opportunity to explore the ability of CD8 ImmunoPET to visualize the dynamics of whole-body CD8+ cell distribution within the context of engineered TIL therapy and TIL restimulation” said Kristin Schmiedehausen, MD, VP, Medical Affairs. “By integrating CD8 ImmunoPET imaging into this investigation, we aim to provide researchers like Dr. Schoenfeld with tools to better understand the mechanism of action of new therapeutic approaches, to facilitate the development of potential new breakthrough technologies in cancer treatment and, to contribute to the ultimate goal of improving patients’ outcomes”.
